Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Articles|April 22, 2022
Daily Medication Pearl: Pilocarpine (Vuity)
Author(s)Saro Arakelians, PharmD
Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.
Advertisement
Medication Pearl of the Day: Pilocarpine (Vuity)
Indication: Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.
Insight:
- Dosing:Instill 1 drop of Vuity in each eye once daily.
- Dosage forms: Ophthalmic solution containing pilocarpine hydrochloride 1.25%.
- Adverse events:Most common adverse reactions (>5%) are headache and conjunctival hyperemia.
- Mechanism of action: Pilocarpine hydrochloride is a cholinergic muscarinic agonist that activates muscarinic receptors located at smooth muscles, such as the iris sphincter muscle and ciliary muscle. Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. Vuity also contracts the ciliary muscle and may shift the eye to a more myopic state.
- Manufacturer: Allergan
Source:
Advertisement
Related to this article
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5